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affecting the young children below 5 years of age in devel-
oping countries like India.
Measles morbidity and mortality has shown a declin-
ing trend in India because of increasing vaccine coverage.
Measles coverage level for India is 90% and for Delhi the
coverage level is 85%. In India there is paucity of data for
measles.
Thus, the present study was proposed with the following
objectives:
• To estimate the incidence of measles among under ﬁve
children of slum of Madipur.
• To estimate the vaccination coverage for measles in under
ﬁve children of slum of Madipur.
Material and Methods: A cross - sectional study was done
in the slum of Madipur, West Delhi, India on all children from
0-59 months of age of the slum area. The slum is divided in
to 6 blocks A, B, C, D, E and F.
Total 781 children were included ie. 130 children from
each block and their parents were interviewed through pre-
formed, pretested, structured questionnaire.
Operational Deﬁnition for Suspect Measles Case: Any
child with fever and maculopapular rash (i.e. non-vesicular)
and cough, coryza (i.e. runny nose) or conjunctivitis (i.e.
red eyes).
Results: Measles vaccination coverage in slum was 77.8%.
79.6% male children and 75.5% female children were immu-
nized. The annual incidence of measles was 6.1%. Amongst
measles cases only 3.1% were immunized and 16.7% were
unimmunized The commonest reason for non vaccination
was unawareness of the need (48%) for vaccination.56.25%
0f measles cases were treated outside the house most com-
monly by a private practitioner. 47.9% children with measles
developed complications due to measles.
Conclusions: The immunization status was much below
the national target of 90% and Delhi target of 85%.immu-
nization status was better in males than in females. The
incidence of measles was high. Measles occurred more in
unimmunized than in immunized. Lack of awareness for
measles vaccination was also observed.
doi:10.1016/j.ijid.2008.05.381
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Background: Clearance of hepatitis B infection is asso-
ciated with T-cell responses to hepatitis B core antigen
(HBcAg). Emergent has developed an attenuated Salmonella
typhi vector (spi-VECTM) carrying an HBcAg gene under the
control of an in vivo regulated promoter (M04NM11).
Methods: 30 healthy subjects aged 18-50 years received
two doses of M04NM11 at a 56 day interval (10
subjects108 cfu, 20 subjects 109 cfu). Peripheral blood
mononuclear cells were collected before treatment and 14
and 28 days after each immunisation for HBcAg assays.
PBMCs were incubated with puriﬁed recombinant HBcAg
(rHBcAg) or one of four peptide pools each containing 4 or
5 sequential synthetic 20-25 residue peptides. Supernatants
were assayed for interferon gamma and IL-5 by ELISA.
Other assays were performed for:
• T-cell proliferation in response to HBcAg or the peptide
pools
• IgM and total Ig to HBcAg
• IgG to S. typhi LPS
• IgA antibody secreting cells (ASC) to S. typhi LPS
• Stool culture daily till day 7, then 11, 14, 21 and 28 days
after immunisation
• Aerobic blood culture 4, 7, 11, 14 and 28 days after immu-
nisation.
Results: Immunogenicity results are shown in the Table
below.
There were no serious adverse events or withdrawals due
to adverse events.
The vaccine strain was not detected in any blood culture
and there were no stools positive after day 5.
Conclusion: M04NM11 given as two doses at a 56 day
interval at doses of 108 and 109 cfu/dose induced a speciﬁc
interferon gamma T-cell response to HBcAg.
doi:10.1016/j.ijid.2008.05.382
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Objectives: To identify operational bottlenecks in the
delivery of immunization program and; to ascertain impact
of the interventions aimed at improving extent of age appro-
priate immunization.
Methods: Study was conducted in community develop-
ment block of a north Indian state from July 2005 to
December 2006. Delivery of immunization program was crit-
ically reviewed by observation of facilities and outreach
sessions, and interview of the caretakers of dropout chil-
dren. An intervention package was evolved with community
volunteers at sub health centre level serving as critical
input along with better program management. All exist-
ing children under 18 month of age and new births during
study period were enrolled and their immunization data was
recorded. Mean age at vaccine administration was computed
for DPT doses and trend of age appropriate immunization
coverage was estimated at 5% signiﬁcance level.
Findings: Staff shortage, non-adherence to micro-
planning, and vaccine stock outs led to delayed immuniza-
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tion. The cohort of new births, indicative of interventions’
impact, had signiﬁcantly lower mean ages at administra-
tion for DPT 2 and DPT 3 (p < 0.0001). Statistically signiﬁcant
trend in decline was observed for mean age at DPT 1, DPT
2 and DPT 3 from ﬁrst to sixth quarter of study period
(p < 0.0001).
Conclusion: Better programme management can improve
performance levels. Community volunteers can increase
outreach services. Government of India’s recent health sec-
tor reforms of decentralization which provide ﬂexibility
at the district level and below to hire contractual staff
and introduction of community volunteer called Accred-
ited Social Health Activists (ASHA) under the National Rural
Health Mission (NRHM) is likely to strengthen immunization
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Background: Inﬂuenza vaccines are currently produced
using embryonated chicken-eggs for inﬂuenza virus prop-
agation. Mammalian cell cultures have been employed as
an alternative technology, primarily to overcome some lim-
itations of current inﬂuenza vaccine manufacture from
embryonated eggs. This study aimed to evaluate the safety
and tolerability of a new cell culture-derived trivalent
inactivated inﬂuenza vaccine (CCIV) (OPTAFLU®, Novartis
Vaccines), produced using Madin-Darby canine kidney cell
culture, and demonstrate its immunological non-inferiority
to an egg-based trivalent inactivated inﬂuenza vaccine (TIV)
(Agrippal S1®, Novartis Vaccines).
Methods: In a Phase III study, 1300 adult (18—60 years
of age) and 1354 elderly (≥61 years of age) subjects were
randomized (1:1) to receive one dose of either CCIV or
TIV. Solicited local and systemic reactions within 7 days,
all adverse events (AE) up to Day 22, and all serious
AE and AE leading to withdrawal up to 6 months were
evaluated. Immunogenicity was assessed 3 weeks after
vaccination, in compliance with European Committee for
Medicinal Products for Human Use (CHMP) criteria, using the
hemagglutination-inhibition (HI) assay.
Results: Solicited local or systemic reactions experienced
in both vaccine groups were mostly mild or moderate in
severity. There were no differences in the immune responses
induced by either of the two vaccines for each of three
inﬂuenza strains (A/H1N1, A/H3N2 and B). In adults, post-
vaccination seroprotection rates (HI titer ≥40 IU) were
90—99% and 91—99% for CCIV and TIV groups, respectively. In
elderly subjects, post-vaccination seroprotection rates were
85—97% and 85—98% for CCIV and TIV groups, respectively.
Both vaccines met all three CHMP criteria in both age groups
and the CCIV met predeﬁned criteria for non-inferiority.
Conclusion: The CCIV was as safe and well tolerated as
the TIV, and was immunologically non-inferior to the TIV.
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The ﬁrst recorded major outbreak of Japanese Encephali-
tis (JE) in Sri Lanka occurred in 1985—86 with 385 cases and
64 deaths in the North Central province. Outbreaks occurred
in 1986—87, 1987—88, the latter being the largest with 812
cases and 192 deaths with the spread to three adjoining
districts. The affected were rice cultivating areas with a
network of irrigation canals supported by seasonal, moder-
ate to heavy rainfall. Children in the age group 5—9 and
young adults in 20—24 years were predominantly affected.
Though JE was prevalent in endemic districts, it was
spreading to newer areas of previous low transmission. To
cope with this emerging challenge, immunization against JE
was initiated on phase basis in 1988. Children aged 1—10
years were offered three primary doses and a booster of
inactivated vaccine in the interpandemic period in a cam-
paign approach. Over the years, immunisation coverage
increased with the reduction of JE incidence. However, cases
and occasional outbreaks were reported in other districts
where immunization was not carried out resulting in exten-
sion of the immunization to 18 districts.
Simultaneously, there was an increasing trend of adverse
events following JE vaccine partly attributable to the change
of the product with possible adverse repercussions on the
JE immunization programme. The other obstacle was the
increasing cost of the inactivated vaccine which amounted
to US$4.50 per a dose in 2006. The high vaccine cost was
a prohibitive factor to sustain the programme of JE immu-
nization. Therefore, an affordable, safe and immunogenic
vaccine alternative was a high priority.
Against this background, live JE vaccine (LJEV) SA 14-14-
2 appeared to be an appropriate, low cost, safe and potent
alternative. To ascertain the safety and immunogenicity of
LJEV, with the support of the PATH in 2007, a clinical trial
was conducted by the Epidemiology Unit. Based on pre-
liminary results of the trial, Sri Lanka has now decided to
introduce LJEV in place of the inactivated vaccine to the
JE Immunization Programme and hopefully to the EPI very
soon.
Currently, the Ministry of Health is negotiating to receive
a public price for procurement of JELV. Details of the sug-
gested schedule are yet to be decided. However, cost savings
from LJEV will enable the introduction of beneﬁts of new
vaccines to Sri Lankan children and, on an optimistic note,
LJEV to adults in high endemic areas in the future.
doi:10.1016/j.ijid.2008.05.385
